Biotechnology

Filter

Current filters:

None

Popular Filters

1980 to 2004 of 2299 results

Pharming in deal with Hyupjin for Ruconest in South Korea

27-03-2012

Dutch biotech firm Pharming Group (NYSE Euronext: PHARM) has entered into an agreement with Seoul-based…

Asia-PacificBiotechnologyHyupjin CorpLicensingPharmingRare diseasesRhucinRuconest

EMA strengthens policies on handling of conflicts of interest

26-03-2012

The European Medicines Agency says that, following its implementation in September 2011, the Management…

BiotechnologyEuropeFinancialPharmaceuticalRegulation

Islet Sciences closes stock acquisition of diabetes drug developer DiaKine

26-03-2012

New York. USA-based biotech company Islet Sciences (OTC.BB: ISLT),said Friday that it has closed its…

BiotechnologyDiabetesDiaKine TherapeuticsIslet SciencesMergers & Acquisitions

Shaking-up gene delivery in the neurodegenerative disease world

25-03-2012

San Diego-based Ceregene, which is developing a novel neurotrophic factor gene therapy delivery via adeno-associated…

BiotechnologyCeregeneNeurologicalResearch

Anaphore buys Chinese firm RuiYi for GPCR biologics platform

23-03-2012

Privately-held US company Anaphore says it has acquired Shanghai, China-based RuiYi, bringing the company…

AnaphoreAsia-PacificBiotechnologyMergers & AcquisitionsRuiYi

US FDA ties up another Biosimilars loose end

23-03-2012

The US Food and Drug Administration issuance of three long-awaited and highly anticipated draft biosimilar…

BiotechnologyGenericsNorth AmericaRegulation

US TREAT Act poised to revolutionize the biotechnology industry

22-03-2012

In recent years, smaller biotechnology companies have received less funding from venture capitalists…

BiotechnologyFinancialLegalNorth AmericaRegulation

NicOx takes option to buy UK ophthalmic company

22-03-2012

French biotechnology firm NicOx (Euronext Paris: COX) has entered into an agreement to acquire 11.8%…

AltacorBiotechnologyMergers & AcquisitionsNicOxOphthalmicsPharmaceutical

ABPI and BIA see UK Budget statement as helping the sectors

22-03-2012

The Budget statement yesterday by UK Chancellor of the Exchequer George Osborne was broadly supported…

BiotechnologyEuropeFinancialPharmaceuticalResearch

Index Ventures debuts new Life Sciences Fund, partnered by GSK and J&J

21-03-2012

Index Ventures says it has launched its first fund solely dedicated to making investments in the life…

BiotechnologyFinancialGlaxoSmithKlineIndex VenturesJanssenJohnson & JohnsonPharmaceutical

Ablynx extends Nanobody deal with Boehringer

21-03-2012

Belgian drug developer Ablynx (Euronext Brussels: ABLX) yesterday announced a two-year extension of the…

AblynxBiotechnologyBoehringer IngelheimImmunologicalsLicensingOncologyPharmaceuticalRespiratory and Pulmonary

New IP legislation will encourage medical research in Australia, says trade group

20-03-2012

New legislation overhauling the Australian patent system will encourage medical research and bring Australia…

Asia-PacificBiotechnologyLegalPatentsPharmaceuticalResearch

Halo Thera lead candidate for Duchenne ready for the clinic

20-03-2012

Privately-held US clinical stage biopharma firm Halo Therapeutic says that an independent review of its…

BiotechnologyHalo TherapeuticshalofuginonePharmaceuticalRare diseasesResearch

Grifols acquires 51% stake in Araclon Biotech

19-03-2012

Spanish plasma products specialist Grifols (MCE: GRF) has acquired 51% of the equity of Zaragoza, Spain-based…

Araclon BiotechBiotechnologyGrifolsMergers & AcquisitionsNeurologicalPharmaceuticalVaccines

XTL Bio enters collaboration with Clalit

18-03-2012

Israeli company XTL Biopharmaceuticals(TASE: XTL) has entered into a strategic collaboration framework…

BiotechnologyClalitResearchRest of the WorldXTL Biopharmaceuticals

Novartis unit buys rights to ThromboGenics eye drug

16-03-2012

Belgian biopharma company ThromboGenics (Euronext Brussels: THR) revealed this morning that it has entered…

AlconBiotechnologyLicensingNovartisocriplasminOphthalmicsPharmaceuticalThromboGenics

Likelihood of big uptake of biosimilars by 2020 questioned

15-03-2012

The engine of the biosimilar sector is the same as with small molecule drugs, patent expiry. On this…

BiotechnologyGenericsGlobalMarkets & MarketingPatentsRegulation

Vivalis signs another EB66 out-licensing deal for MAb production

14-03-2012

French biotech firm Vivalis (NYSE Euronext: VLS) has signed a joint collaboration and commercial license…

BiotechnologyEB66LicensingVaccinesVivalis

Pfizer and Biocon cancel biosimilars deal

14-03-2012

Indian biotech firm Biocon (BSE: 532523) and global drugs behemoth Pfizer (NYSE: PFE) yesterday announced…

Asia-PacificBioconBiotechnologyDiabetesInsulinLicensingNovo NordiskPfizerPharmaceutical

Epistem in fibrosis research deal with GlaxoSmithKline

13-03-2012

UK biotech and personalized medicines company Epistem (LSE:EHP) has entered into a three year biomarker…

BiotechnologyEpistemGlaxoSmithKlineLicensingPharmaceuticalResearch

NicOx earns $10M milestone under Bausch & Lomb accord

13-03-2012

French biotechnology firm NicOx (Euronext Paris: COX) will receive a $10 million milestone from US partner…

Bausch & LombBiotechnologyFinancialNicOxOphthalmicsPharmaceuticalResearch

Valeant on acquisition trail again

12-03-2012

In a third acquisition deal announced so far this year, Canada-based Valeant Pharmaceuticals International…

BiotechnologyMergers & AcquisitionsPele Nova BiotecnologiaPharmaceuticalRegedermSouth AmericaValeant Pharmaceuticals

1980 to 2004 of 2299 results

Back to top